Clonal heterogeneity is hidden in the mix

Algorithm reconstructs lineages of competing cancer cells within individual tumours

Clonal heterogeneity is hidden in the mix

140529-clonal.pngDOI: 10.1016/j.celrep.2014.04.055
Reconstruction of clonal heterogeneity. (A) Schematic view of subclonal diversification. In this example, mutations in daughter cells of a single founder cell (left) diverge into subclones (reflected by different colours). Two point mutations occur early on with a subsequent gain of a chromosome arm and a short deletion at a later stage, each followed by clonal expansion (subclones 1, 2, and 4). A short-lived lineage arises independently (subclone 3). (B) DNA sequencing of a cell population in a tumour sample and a matched normal can be used to infer the underlying population structure.

Researchers at the Wellcome Trust Sanger Institute have developed a method to characterise the main lineages of cells that are present in a tumour and their prevalence over time following chemotherapy. Aiming to reconstruct the genetic profiles of cellular lineages within the tumour, the team created a new computational algorithm named cloneHD which makes use of whole-genome DNA sequencing from mixed populations.

Cells in a tumour originate from a normal cell giving rise to billions of malignant, genetically diverse cells. Genome-wide approaches to study clonal heterogeneity are hampered by limited resolution of subpopulations, since short-read sequencing of mixed cell populations does not yield a direct readout of their clonal identity. There is mounting evidence for genetic heterogeneity in the majority of cancer types, which can translate in a differential response to treatment.

To address this problem, the algorithm uses short-read sequence data that can be related to different types of aberrations within all the genomes in a population to carry out its analysis. By combining these data the researchers can identify and describe the major lineages of genetically distinct cancer cells, also known as clones. The algorithm classifies cells into groups, discriminating different cell populations that belong to each of the clonal lineages. At the genetic level, the algorithm can assign aberrations by clone: somatic changes to single letters and copy-number changes in the genetic code, as well as allelic imbalances in the germline caused by these events.

"Our cloneHD algorithm helps us generate useful insights into cancer development and the effects of treatment, by delineating cell lineages within the tumour and their progression over time."

Dr Ville Mustonen, senior author from the Sanger Institute

To test that the algorithm can trace clonal dynamics in cancer, the researchers retrospectively explored temporal changes in a case study of a patient with chronic lymphocytic leukaemia, from whom sequence data had been collected at five different time points during the course of treatment. Such retrospective analysis is helpful to better understand tumour evolution. They further performed a mimic of real-time monitoring by progressively adding more samples to see if prospective analyses are of potential clinical relevance.

"The algorithm allowed us to see that the dominant lineage of tumour cells diminished in response to treatment, but that another lineage of drug-resistant cells had started to rise in numbers. It is possible that, using this approach in conjunction with near real-time data collection, clinicians will be able to identify when a treatment is starting to fail."

Dr Andrej Fischer, first author from the Sanger Institute

In the near future, the team will test the algorithm and its potential clinical applications using larger data sets and a wider range of cancer types. Beyond cancer, a quantitative understanding of clonal dynamics translates to other organisms facing environmental stresses, such as bacteria, parasites or viruses.

Notes to Editors
Publications
  • High-definition reconstruction of clonal composition in cancer.

    Fischer A, Vázquez-García I, Illingworth CJR and Mustonen V

    Cell reports 2014;7;5;1740-1752

Funding

This work was funded by the Wellcome Trust, the German Research Foundation (DFG) and a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society.

Participating Centres
  • Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
  • Department of Applied Mathematics and Theoretical Physics, Centre for Mathematical Sciences, University of Cambridge, Cambridge, UK
  • Department of Genetics, University of Cambridge, Cambridge, UK
Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

500,000 whole human genomes will be a game-changer for research into human diseases
Following on from a successful pilot at the Sanger Institute, we are leading a project to sequence the genomes of all UK Biobank volunteers to power the next wave of genetic and health research
Brown trout genome will help explain species' genetic superpowers
Eagerly awaited reference genome will allow conservationists to understand how the fish adapts to marine and freshwater environments
LifeLab 2019 – discovery on your doorstep with an exciting programme of free events and activities
LifeLab has launched an exciting programme of events for Friday 27 and Saturday 28 September 2019, transforming parts of Cambridge, Peterborough and Ely into discovery zones for the weekend